Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RNAC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Decartes-08 | Myasthaenia Gravis | Phase 3 · NCT06799247 | Active not recruiting |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+… | Myeloma Multiple | Phase 2 · NCT04816526 | Terminated |
| Autologous Anti-BCMA CD8+ CAR T-cells… | Multiple Myeloma | Phase 2 · NCT04436029 | Completed |
| Descartes 30 | Acute Respiratory Distress Syndrome | Phase 1 · NCT04524962 | Terminated |
| Descartes-15 | Refractory Multiple Myeloma | Phase 1 · NCT06304636 | Terminated |
| Descartes-25 | Multiple Myeloma | Phase 1 · NCT05113342 | Terminated |
| Fludarabine | Multiple Myeloma | Phase 1 · NCT03994705 | Terminated |
Also used in these trials (approved or third-party drugs, not RNAC's own candidates): Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RNAC holds $123M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.4M/quarter from operations, an estimated runway of 15.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNAC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Timothy A Springer Director, 10% owner · +7,800 options |
Insider | 9,633,493 | 31.58% | 2026-01-02 |
| Murat Kalayoglu 10% owner · +41,462 options |
Insider | 5,820,260 | 19.08% | 2026-04-02 |
| Elizabeth Hoge 10% owner · +33,662 options Includes shares also reported by Murat Kalayoglu, counted once |
Insider | 5,820,260 | 19.08% | 2026-04-02 |
| Squarepoint Ops LLC | Institution (13G, 5%+) | 2,209,601 | 7.24% | 2026-03-09 |
| Blackrock Inc. | Institution (13F) | 808,458 | 2.65% | 2026-09-30 |
| 683 Capital Management LLC | Institution (13F) | 751,000 | 2.46% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 555,823 | 1.82% | 2026-09-30 |
| FMR, LLC | Institution (13F) | 370,457 | 1.21% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 367,350 | 1.20% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 342,829 | 1.12% | 2026-09-30 |
| Carsten Brunn President and CEO, Director · +783,833 options |
Insider | 323,530 | 1.06% | 2026-01-06 |
| AQR Capital Management, LLC | Institution (13F) | 287,156 | 0.94% | 2026-09-30 |
Share count 30,503,005 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-04-02 filed 2026-04-06 |
Seven One Eight Three Four… |
Option exercise (M) | 758,001 | – | 5,313,261 |
| 2026-04-02 filed 2026-04-06 |
Seven One Eight Three Four… |
Option exercise (M) | 22,740 | – | – |
| 2026-04-02 filed 2026-04-06 |
Kalayoglu Murat |
Option exercise (M) | 758,001 | – | 5,313,261 |
| 2026-04-02 filed 2026-04-06 |
Kalayoglu Murat |
Option exercise (M) | 22,740 | – | – |
| 2026-03-13 filed 2026-03-13 |
Singer Michael |
Gift (G) | 6,555 | – | 49,578 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNAC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →